JNJ-79635322 vs Teclistamab for Multiple Myeloma

(TRIlogy-4 Trial)

Recruiting at 42 trial locations

Overseen By Study Contact

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Janssen Research & Development, LLC

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

400 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

Are You a Good Fit for This Trial?

Inclusion Criteria

I've had 3 types of treatments for myeloma, including PI, IMiD, and anti-CD38.

I have been diagnosed with multiple myeloma.

My disease can be measured by tests.

What Are the Treatments Tested in This Trial?

Interventions

• JNJ-79635322
• Teclistamab

How Is the Trial Designed?

Group I: JNJ-79635322 Experimental Treatment 1 Intervention

Participants will receive subcutaneous (SC) dose of JNJ-79635322 until progressive disease (PD) or intolerable toxicity.

Group II: Anti BCMAxCD3 Bispecific Antibody Active Control 1 Intervention

Participants will receive teclistamab (an Anti BCMAxCD3 bispecific anitbody) as a SC injection until PD or intolerable toxicity.

Who Is Running the Clinical Trial?

Janssen Research & Development, LLC

Lead Sponsor

Trials

1,022

Recruited

6,408,000+

Joaquin Duato

Janssen Research & Development, LLC

Chief Executive Officer since 2022

MBA from ESADE, Master of International Management from Thunderbird School of Global Management

Dr. Jijo James, MD

Janssen Research & Development, LLC

Chief Medical Officer since 2014

MD from St. Johns Medical College, MPH from Columbia University